Circulating DNA in solid organ cancers-analysis and clinical application.
Circulating tumour DNA (ctDNA) is that fraction of circulating DNA that is derived from a patient's cancer. For a number of years, patients with haematological malignancies have had their disease diagnosed or monitored using tests based on detecting specific cytological or molecular biomarkers in blood. It has long been appreciated that the more common epithelial malignancies also shed DNA into the blood and that this tumour-derived DNA generally contributes a minor percentage of the overall cell-free DNA burden in peripheral blood. The biotech revolution has transformed our ability to detect, quantify and interpret genetic events. This has led to a renewed interest in the potential of using a simple blood test to both diagnose cancer and longitudinally monitor the response to medical interventions in patients with solid organ malignancies.In this review we provide a summary of the literature to date and describe the main attributes of the current analytical approaches to ctDNA. We then focus on the potential clinical applications. There is increasing evidence to support the routine analysis of ctDNA in clinical decision-making for certain subgroups of patients with so-called hotspot mutations, particularly in lung and colorectal cancer. With continued refinement and technological progress, non-invasive molecular biomarkers including of ctDNA may be clinically useful at all stages of cancer management from diagnosis to disease progression.
From the 1Department of Asthma, Allergy and Lung Biology, King's College London, London SE1 9RT, UK and.
E
E
Karampini
From the 1 Department of Asthma, Allergy and Lung Biology, King's College London, London SE1 9RT, UK and.|Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1GA.
F
F
McCaughan
D014408:Biomarkers, Tumor / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood / Q000175:diagnosis*; D004273:DNA, Neoplasm / Q000097:blood*; D018450:Disease Progression; D055088:Early Detection of Cancer; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis*; D009154:Mutation
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm